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Introduction: Peripheral nerve hyperexcitability disorders are characterized by constant muscle fiber activity. Acquired
neuromyotonia manifests clinically in cramps, fasciculations, and stiffness. In Morvan’s syndrome the signs of peripheral
nerve hyperexcitability are accompanied by autonomic symptoms, sensory abnormalities, and brain disorders.
Case presentation: A 70-year-old Caucasian man developed, in the course of 3 months, polyneuropathy with
unpleasant dysesthesia of lower extremities and gradually increasing fasciculations, muscle stiffness and fatigue.
Subsequently, he developed a prominent insomnia with increasing psychological changes and then he attempted a
suicide. Electromyography confirmed a sensory-motor polyneuropathy of a demyelinating type. The findings included
fasciculations as well as myokymia, doublets and multiplets, high frequency discharges, and afterdischarges, following
motor nerve stimulation. No auto-antibodies were found either in his blood or cerebrospinal fluid. Magnetic resonance
imaging of his brain showed small, unspecific, probably postischemic changes. A diagnosis
of Morvan’s syndrome was confirmed; immunoglobulin (2g/kg body weight) was applied intravenously, and,
subsequently, carbamazepine 2×200mg, venlafaxine 150mg, and mirtazapine each night were prescribed. His sleep im-
proved, suicidal tendencies stopped, less fasciculations occurred, and muscle hypertonia also improved. Hyperexcitation
also partially remitted including the electromyography finding.
Conclusions: We described here the case of a patient with Morvan’s syndrome; his case is rare because of severe
psychical changes with a suicide attempt, short admission to a psychiatric ward, prominent electromyographic
changes, and because antibodies were not detected. After therapy with immunoglobulins followed by corticosteroids
with sodium channel blocker, his motor, autonomic, psychical signs and symptoms, and electromyography changes
substantially improved.
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Peripheral nerve hyperexcitability disorders are character-
ized by constant muscle fiber activity due to hyperexcitabil-
ity in the distal motor axons [1]. Acquired neuromyotonia
is characterized by continual ectopic nerve activity, which
manifests clinically in cramps, fasciculations, and stiffness.
These symptoms are accompanied by autonomic symp-
toms, sensory abnormalities, and, in the case of Morvan’s
syndrome, by brain disorders. Apart from neuromyotonia,
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article, unless otherwise stated.hallucinations, anxiety, agitation, confusion), autonomic
symptoms (hyperhidrosis, tachycardia, obstipation) [2]. On
neurophysiological examination, neuromyotonia manifests
prominent spontaneous activity: fibrillations, positive waves,
fasciculations, myokymia, multiple discharges, neuromyo-
tonic discharges, doublets and multiplets. After voluntary
contraction, and after electric stimulation of motor fibers,
multiple and long-lasting afterdischarges occur [2]. There is
no clear consensus as to the part of the peripheral motor
neuron in which this ectopic activity arises. Most authors
locate the ectopic focus in distal terminal motor fibers. Both
antidromic propagation of excitation and axon reflex can
participate in triggering this ectopic activity. In some condi-
tions (inflammatory changes of the central nervous system;Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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horn of the spinal cord as well as in higher levels of the
CNS [3].
Case presentation
This case report describes a 70-year-old Caucasian man
with presented, and electrophysiologically confirmed, neu-
romyotonia with significant autonomic and psychological
changes (insomnia, anxiety, suicidal behavior), and subse-
quent successful treatment.
In April 2014, the 70-year-old man developed crural and
leg pain, chills, tingling, hypersensitivity to mechanic
stimuli, and slight weakening of lower limbs with mild foot-
drop. This disorder developed quickly and no trigger was
identified. In June 2014, he developed insomnia, anxiety,
confusion, even auditory hallucinations, and he attempted
suicide by slashing his left wrist. For a short period of time,
he was admitted to a psychiatric ward.
He was referred to our neurological clinic electro-
myography (EMG) laboratory because of muscle weak-
ness with prominent fasciculations, myokymia, and
suspected amyotrophic lateral sclerosis. An EMG con-
firmed fibrillations, positive waves, fasciculations, and
multiple myokymic and neuromyotonic discharges,
occasional high frequency fasciculations, doublets and
multiplets (Figure 1). Contraction curve was reduced
with unstable motor unit potentials with neurogenic
changes. A motor nerve conduction study showed
multiple afterdischarges with long-lasting repetitions,
which prevented F-waves assessment (Figure 2). His
grip strength was weakened. He could briefly stand on
tiptoes but only with difficulties; walking on heels wasFigure 1 Neuromyotonic discharge in musculus gastrocnemius medialis; rionly barely attempted. He also presented tactile, thermic
and vibratory hypesthesia of his lower and upper limbs.
His blood test showed high levels of creatine kinase (CK)
12.26 (nkat/L; normal value 3.60), CK myocardial bound
0.52, but no other abnormalities. No antibodies (contactin
associated protein-like 2, CASPR2; leucine-rich glioma inac-
tivated 1 protein; contactin 2; anti-glutamic acid decarboxyl-
ase) were found in his blood or in his cerebrospinal fluid
(CSF). Oligoclonal protein synthesis was not confirmed.
Cancer was not detected (oncological markers were nega-
tive; the results of chest X-ray, ultrasonography of abdomen,
endoscopic investigation of gastrointestinal tract and uro-
logical examination were negative). His CSF showed border-
line results: protein 0.40g/L and 1 mononuclear cell/1mm3.
The findings were evaluated as neuromyotonia associated
with central cerebral symptoms consistent with Morvan’s
syndrome. No antibodies (including voltage-gated potas-
sium channel, VGKC, and CASPR2) were found either in
his blood or CSF.
For a period of 5 days, immunoglobulin was applied
intravenously at a dosage of 0.4g/kg body weight. A rapid
improvement in his muscle strength occurred, his fascicu-
lations decreased, and his pain sensation disorders were
alleviated, including hyperalgesia. Subsequently, venlafax-
ine 150mg, carbamazepine 2×200mg, and mirtazapine
30mg each night were prescribed. Both his sleep disorder
and daytime fatigue were alleviated. A follow-up EMG
showed an increased A-sensory nerve action potential and
shortened duration of afterdischarges. His blood CK level
decreased to 2.31nkat/L. He was discharged after 14 days.
A follow-up examination confirmed stable state; he had
no sleep disorder, hallucinations or depression.ght.
Figure 2 High voltage and long-lasting afterdischarges F-wave study in tibial nerve; left.
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an autoimmune type with undetected specific antibodies.
He has been treated with prednisolone and carbamaze-
pine for more than 8 months and is still without substan-
tial cramps, profuse sweating and psychical problems. We
expect from the facts that his outcome will be good [2,4].
Discussion
We described here the case of a 70-year-old man with
Morvan’s syndrome; his case is rare because of his severe
psychical changes (a suicide attempt and short admission
to a psychiatric ward), prominent electromyographic
changes, and because antibodies were not detected. In pa-
tients with Morvan’s syndrome without antibodies their
therapy should begin with intravenous immunoglobulins
(IVIGs) followed by corticosteroids and with sodium
channel blocker. After this recommended therapy the
motor, autonomic, psychical signs and symptoms, and
some of the neurophysiologic changes in our patient
substantially improved.
An acquired neuromyotonia is frequently associated with
autoimmune disorders, thymus cancer, lymphoma, or lung
cancer. Morvan’s syndrome is characterized by neuro-
myotonia, prominent autonomic symptoms (hyperhidrosis,
obstipation, and tachycardia) and cerebral symptoms: in-
somnia, agitation, anxiety, confusion, and hallucinations.
Patients with Morvan’s syndrome display prominent leg
pain, which sometimes becomes a burning sensation, andmyalgia [4]. In Morvan’s syndrome, antibodies against
VGKCs are confirmed. These antibodies cause a reduction
in the number of potassium channels, and thus prolong
nerve action potential on the axon membrane [3]. Anti-
bodies against VGKC occur in hyperexcitability of the
peripheral nerve, as well as in limbic encephalopathy,
epileptic seizures, and myoclonus; that is the reason why
some authors use the term “VGKC syndromes”. Antibodies
are found in 30 to 50% of patients with neuromyotonia and
in the majority of patients with Morvan’s syndrome [5]. We
failed to detect any antibodies or tumor in our patient. Also
other authors describe patients with Morvan’s syndrome of
autoimmune origin without detection of VGKC. Our
diagnosis was based on clinical findings, medical history,
and predominantly on neurophysiological findings.
Therapy of Morvan’s syndrome is focused on suppression
of antibody production, influencing ion channels, and, sub-
sequently, neuropathic pain control. In patients with posi-
tive findings of VGKC antibodies it is recommended to
commence the therapy with plasmapheresis with subse-
quent oral immunosuppressive therapy applying corticoids
or azathioprine [5]. In patients without VGKC antibodies
plasmapheresis is not efficient, and it is recommended
to start with a full dose of IVIG (2g/kg body weight),
and then continue with a maintenance dose of corti-
coids [3]. Carbamazepine at a dose of 400 to 600mg per
day leads to disappearance of fasciculations and neuro-
pathic pain [2].
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Morvan’s syndrome is characterized by motor symp-
toms (neuromyotonia), neuropathic pain, autonomic
dysfunction and cerebral symptoms (including insomnia
and confusion). Clinical presentation and neurophysio-
logical findings are essential for diagnosis determin-
ation, whereas VGKC antibodies are detected only in
50% of cases. In Morvan’s syndrome without detected
antibodies, it is efficient to apply IVIG with subsequent
oral therapy by corticosteroids and potassium channel
blockers to reduce autonomic symptoms and neuro-
pathic pain. An efficient therapy significantly alleviates a
patient’s complaints and clinical findings (fasciculation,
pseudomyotonia), as well as improvement of typical
changes detected by neurophysiological examination
(myokymia, discharges, afterdischarges).
We described here a case of a 70-year-old man with se-
vere Morvan’s syndrome; his case is rare because of prom-
inent psychical changes (short hospitalization in psychiatric
ward, suicide attempt), severe neurophysiological findings,
and because he had no antibodies. After immunomodula-
tion therapy his clinical and electrophysiological findings
partially improved. He was recommended to our EMG lab
with suspicion of amyotrophic lateral sclerosis because of
the prominent fasciculations in his muscles and weight loss.
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